FHTX vs RMD · rev $19.3M vs P/E 29, rev $5.65B
Foghorn Therapeutics Inc (FHTX) versus ResMed Inc (RMD) — a side-by-side from cached financials, not a winner call.
Foghorn Therapeutics Inc (FHTX) is a biotechnology company listed on NASDAQ.
ResMed Inc (RMD) is a medical instruments & supplies company listed on US.
Latest reported FHTX revenue for 2026-06-30 was $19.3M. Net income was -$27.1M. FHTX currently screens at market cap $237.8M.
Latest reported RMD revenue for 2026-06-30 was $5.65B. Net income was $1.52B. Revenue was up 9.9% from 2025-06-30 to 2026-06-30. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
FHTX currently screens at market cap $237.8M. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
Not investment advice. Open the FHTX and RMD stock pages for the full models.
Not investment advice.